LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

Search

Apellis Pharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

17.41 -5.38

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

17.35

Max

18.37

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-56M

-92M

Pardavimai

-46M

167M

Pelnas, tenkantis vienai akcijai

-0.74

Pelno marža

-55.292

Darbuotojai

705

EBITDA

-56M

-80M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+93.75% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-07-31

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-333M

2.2B

Ankstesnė atidarymo kaina

22.79

Ankstesnė uždarymo kaina

17.41

Naujienos nuotaikos

By Acuity

50%

50%

162 / 380 reitingas Healthcare

Apellis Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-06-27 20:51; UTC

Uždarbis

These Stocks Moved the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

2025-06-27 20:50; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2025-06-27 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2025-06-27 20:48; UTC

Rinkos pokalbiai

Computer Lobby Cheers Move to Punish Canada Over Digital Tax -- Market Talk

2025-06-27 20:46; UTC

Rinkos pokalbiai

Market Talk Roundup: Latest on U.S. Politics

2025-06-27 20:46; UTC

Rinkos pokalbiai

Canada Dismissal of Risk From Digital Tax Is 'Shocking' -- Market Talk

2025-06-27 19:31; UTC

Rinkos pokalbiai

Canada CEOs Call for Carney to Drop Digital Tax -- Market Talk

2025-06-27 19:19; UTC

Rinkos pokalbiai

Oil Posts Weekly Loss As Geopolitical Premium Evaporates -- Market Talk

2025-06-27 19:16; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

2025-06-27 18:57; UTC

Įsigijimai, susijungimai, perėmimai

Russian Oligarch Roman Abramovich Is Evraz PLC's Largest Shareholder With 29% Stake -- WSJ

2025-06-27 18:57; UTC

Įsigijimai, susijungimai, perėmimai

Evraz North America Parent Evraz PLC Remains Under Sanction by U.K. -- WSJ

2025-06-27 18:57; UTC

Įsigijimai, susijungimai, perėmimai

Evraz North America Employs About 3,400 People, Has 3.5 Million Tons of Finished Steel Capacity -- WSJ

2025-06-27 18:57; UTC

Įsigijimai, susijungimai, perėmimai

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

2025-06-27 18:57; UTC

Įsigijimai, susijungimai, perėmimai

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

2025-06-27 18:42; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-06-27 18:42; UTC

Rinkos pokalbiai

Canada's Carney 'Likely Amenable' to Dropping Digital-Services Tax -- Market Talk

2025-06-27 18:39; UTC

Rinkos pokalbiai
Uždarbis

Nike's Second-Half Prospects Can Get Better as Worst is Behind it -- Market Talk

2025-06-27 18:29; UTC

Rinkos pokalbiai

Canada Recession Risks Likely to Rise With Trump's Termination of Tariff Talks -- Market Talk

2025-06-27 18:18; UTC

Rinkos pokalbiai

Canadian Dollar Sharply Weakens on Trump's Surprise End to US-Canada Tariff Talks -- Market Talk

2025-06-27 18:16; UTC

Rinkos pokalbiai

Trump's Threat Against Canada Weighs Down Treasurys -- Market Talk

2025-06-27 17:16; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Falls by 6 to 432 -- Market Talk

2025-06-27 17:08; UTC

Uždarbis

McDonald's Stock Has Slipped. One Analyst Sees 21% Upside. -- Barrons.com

2025-06-27 16:52; UTC

Įsigijimai, susijungimai, perėmimai

Nike Stock Soars After Earnings. Is It Time to Just Buy It? -- Barrons.com

2025-06-27 16:22; UTC

Uždarbis

These Stocks Are Moving the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

2025-06-27 16:20; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2025-06-27 16:20; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2025-06-27 16:20; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2025-06-27 16:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2025-06-27 15:59; UTC

Rinkos pokalbiai

Gold Futures Slump on Improving Risk Appetite -- Market Talk

2025-06-27 15:56; UTC

Rinkos pokalbiai

Nvidia Again Helping To Power New S&P Highs -- Market Talk

Akcijų palyginimas

Kainos pokytis

Apellis Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

93.75% į viršų

12 mėnesių prognozė

Vidutinis 35.65 USD  93.75%

Aukščiausias 60 USD

Žemiausias 18 USD

Remiantis 18 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Apellis Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

18 ratings

10

Pirkti

8

Laikyti

0

Parduoti

Rinkos nuotaikos

By Acuity

162 / 380 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.